Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study
Eur Urol. 2026 Jan;89(1):71-79.
https://pubmed.ncbi.nlm.nih.gov/41130825/
An international placebo-controlled randomized multicenter trial of nimorazole with accelerated chemo-radiotherapy for locally advanced HPV-negative squamous cell carcinoma of the head and neck (HNSCC)
Radiother Oncol. 2026 Jan;214:111227.
https://pubmed.ncbi.nlm.nih.gov/41138857/
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trial
Radiother Oncol. 2026 Jan;214:111202.
https://pubmed.ncbi.nlm.nih.gov/41173355/
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial
Lancet Oncol. 2026 Jan;27(1):45-56.
https://pubmed.ncbi.nlm.nih.gov/41449147/
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial
Lancet Oncol. 2026 Jan;27(1):23-35.
https://pubmed.ncbi.nlm.nih.gov/41449145/
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results
Int J Radiat Oncol Biol Phys. 2026 Jan 1;124(1):133-146.
https://pubmed.ncbi.nlm.nih.gov/40780546/
Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial
Int J Radiat Oncol Biol Phys. 2026 Jan 1;124(1):109-121.
https://pubmed.ncbi.nlm.nih.gov/40752655/
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial
Lancet. 2026 Jan 24;407(10526):363-374.
https://pubmed.ncbi.nlm.nih.gov/41448222/
Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial
Lancet. 2026 Jan 10;407(10524):174-184.
https://pubmed.ncbi.nlm.nih.gov/41391462/
PDF
Routinely collected health data on 10-year genitourinary and gastrointestinal morbidity after ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer in the randomised, non-inferiority, phase 3 trial HYPO-RT-PC
Radiother Oncol. 2026 Feb;215:111323.
https://pubmed.ncbi.nlm.nih.gov/41389860/
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer
J Clin Oncol. 2026 Feb;44(4):274-285.
https://pubmed.ncbi.nlm.nih.gov/41397208/
Tumor Treating Fields Therapy After Stereotactic Radiosurgery for Brain Metastases From Non-Small Cell Lung Cancer: Final Results of the Phase 3 METIS Study
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):278-293.
https://pubmed.ncbi.nlm.nih.gov/41033612/
O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
Lancet Oncol. 2026 Feb;27(2):169-180.
https://pubmed.ncbi.nlm.nih.gov/41429128/
Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Feb 1;124(2):349-358.
https://pubmed.ncbi.nlm.nih.gov/40876576/
Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: Long-term Data from the SAKK 09/10 Randomised Phase 3 Trial
Eur Urol. 2026 Mar;89(3):199-203.
https://pubmed.ncbi.nlm.nih.gov/41494929/
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial
J Clin Oncol. 2026 Mar;44(7):534-539.
https://pubmed.ncbi.nlm.nih.gov/41512219/
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results
J Clin Oncol. 2026 Mar;44(7):586-597.
https://pubmed.ncbi.nlm.nih.gov/41337691/
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005
J Clin Oncol. 2026 Mar 10;44(8):630-640.
https://pubmed.ncbi.nlm.nih.gov/41529214/
Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
Lancet Oncol. 2026 Mar;27(3):293-301.
https://pubmed.ncbi.nlm.nih.gov/41655576/
Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):604-613.
https://pubmed.ncbi.nlm.nih.gov/41027544/
Hypofractionated Dose Escalation Versus Conventionally Fractionated Radiation Therapy for Patients With Intermediate- and High-Risk Localized Prostate Cancer: Long-Term Results of the HYPRO Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):928-936
https://pubmed.ncbi.nlm.nih.gov/41106690/
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):1024-1032.
https://pubmed.ncbi.nlm.nih.gov/41161645/
Effectiveness of Low-Cost Polyurethane Film in Reducing Dermatitis Severity in Breast Cancer Patients With Higher Fitzpatrick Skin Types Undergoing Hypofractionated Irradiation With Simultaneous Integrated Boost: An Intrapatient Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Mar 15;124(4):952-960.
https://pubmed.ncbi.nlm.nih.gov/41187861/
Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial)
Int J Radiat Oncol Biol Phys. 2026 Mar 1;124(3):692-701.
https://pubmed.ncbi.nlm.nih.gov/41101556/
5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial
Lancet. 2026 Mar 7;407(10532):976-987.
https://pubmed.ncbi.nlm.nih.gov/41794436/
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial
Lancet. 2026 Mar 28;407(10535):1259-1275.
https://pubmed.ncbi.nlm.nih.gov/41875914/
PDF
Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data
Radiother Oncol. 2026 Apr;217:111388.
https://pubmed.ncbi.nlm.nih.gov/41580147/
Neoadjuvant Chemotherapy With CAPOX Versus Chemoradiation for Locally Advanced Rectal Cancer With Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial
J Clin Oncol. 2026 Apr 10;44(11):970-980.
https://pubmed.ncbi.nlm.nih.gov/41712876/
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
N Engl J Med. 2026 Apr 2;394(13):1257-1269.
https://pubmed.ncbi.nlm.nih.gov/41707170/
Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial
Radiother Oncol. 2026 May;218:111334.
https://pubmed.ncbi.nlm.nih.gov/41412437/
Dosimetric Comparison of Magnetic Resonance Imaging Guided Versus Reduced Margin Computed Tomography Guided Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Post Hoc Analysis of a Phase 3 Trial
Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):266-274.
https://pubmed.ncbi.nlm.nih.gov/40482729/
Dosimetric Comparison of CyberKnife and Conventional Linac Prostate Stereotactic Body Radiation Therapy Plans: Analysis of the PACE-B Study
Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):250-256.
https://pubmed.ncbi.nlm.nih.gov/39862896/
Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin
Radiother Oncol. 2026 Jun;219:111479.
https://pubmed.ncbi.nlm.nih.gov/41903611/
Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT
Radiother Oncol. 2026 Jun;219:111490.
https://pubmed.ncbi.nlm.nih.gov/41905637/
Effects of rhuGM-CSF on prevention and treatment of oral mucositis in patients receiving radiotherapy for head and neck cancer: A randomized controlled trial
Radiother Oncol. 2026 Jun;219:111527.
https://pubmed.ncbi.nlm.nih.gov/41966279/
Therapeutic effect of Photobiomodulation therapy on radiation-induced oral mucositis in head and neck Cancer: A prospective double-blind, self-controlled clinical trial
Radiother Oncol. 2026 Jun;219:111495.
https://pubmed.ncbi.nlm.nih.gov/41864516/
Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
Lancet Oncol. 2026 Jun;27(6):673-685.
https://pubmed.ncbi.nlm.nih.gov/42225101/
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
Lancet Oncol. 2026 Jun;27(6):686-698.
https://pubmed.ncbi.nlm.nih.gov/42134381/
CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial
Int J Radiat Oncol Biol Phys. 2026 Jun 1;125(2):489-501.
https://pubmed.ncbi.nlm.nih.gov/41352689/
Hypofractionated Versus Normofractionated Accelerated Radiation Therapy With or Without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO): A Randomized, Open-Label, Phase 3, Noninferiority Trial
Int J Radiat Oncol Biol Phys. 2026 Jun 1;125(2):387-398.
https://pubmed.ncbi.nlm.nih.gov/41711624/
